|
Tom Reynolds joined Seattle Genetics in March 2007. As Chief Medical Officer, he leads clinical and regulatory activities across the company’s product portfolio. Dr. Reynolds has more than 15 years of biotechnology drug development experience, from preclinical development through the FDA approval process. Before joining Seattle Genetics, he was at Zymogenetics from 2002 to 2007, most recently as Vice President, Medical Affairs, where he oversaw the clinical development and BLA filing of rhThrombin and led the Medical Affairs department. Previously, he held various positions at Targeted Genetics including Vice President, Clinical Affairs, and before that was at Somatix Therapy (acquired by Cell Genesys in 1997). Dr. Reynolds holds a B.A. in Chemistry from Dartmouth College and both a Ph.D. in Biophysics and M.D. from Stanford University.
| 